Breaking News Instant updates and real-time market news.

RHHBY

Roche

$0.00 /

+ (+0.00%)

06:36
08/29/19
08/29
06:36
08/29/19
06:36

Roche announces European approval for Tecentriq plus Abraxane for breast cancer

Roche announced that the European Commission has approved Tecentriq plus chemotherapy for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer whose tumours have PD-L1 expression and who have not received prior chemotherapy for metastatic disease. Roche's VENTANA PD-L1 Assay is now CE marked and commercially available in the European Union as an aid for identifying patients with TNBC eligible for treatment with the Tecentriq combination. This approval is based on the results from the Phase III IMpassion130 study. Progression-free survival results demonstrated a statistically significant benefit for Tecentriq in combination with nab-paclitaxel and showed that Tecentriq plus nab-paclitaxel significantly reduced the risk of disease worsening or death by 38% compared with nab-paclitaxel alone in people who were tested positive for PD-L1 expression on tumour-infiltrating immune cells. At the second interim analysis, Tecentriq and nab-paclitaxel showed a clinically meaningful overall survival improvement of seven months vs placebo and nab-paclitaxel in the PD-L1-positive population OS results in the PD-L1-positive population were not formally tested due to the hierarchical design of the study as statistical significance was not met for OS in the intention-to-treat population. The assessment of PD-L1 on tumour-infiltrating immune cells is essential for identifying the patients with TNBC benefiting from this Tecentriq combination. PD-L1 expression status in the IMpassion130 study was assessed by the VENTANA PD-L1 assay. Safety in the Tecentriq plus nab-paclitaxel arm appeared consistent with the known safety profiles of the individual medicines, and no new safety signals were identified with the combination. The nature and incidence of severe adverse events and Grade 3-4 adverse events were consistent with the known safety profiles of the individual study drugs or the underlying disease. SAEs were reported in 23% of people receiving Tecentriq plus nab-paclitaxel compared to 18% of people receiving chemotherapy alone. Grade 3-4 AEs were reported in 49% of people receiving Tecentriq plus nab-paclitaxel compared to 42% of people receiving chemotherapy alone. Currently, there are seven ongoing Phase III studies investigating Tecentriq in TNBC, including early and advanced stages of the disease.

  • 02

    Sep

  • 06

    Sep

  • 09

    Sep

  • 04

    Nov

RHHBY Roche
$0.00 /

+ (+0.00%)

07/26/19 UBS
Roche upgraded to Buy from Neutral at UBS
07/23/19 JPMorgan
Competition questions for Biogen, Ions' Spinraza not dissipating soon, says JPMorgan
07/23/19 BTIG
Adaptive Biotechnologies initiated with a Buy at BTIG
07/17/19 Raymond James
Investors shouldn't overreact to drug proposal headlines, says Raymond James

TODAY'S FREE FLY STORIES

Earnings
CACI raises FY20 EPS view to $11.91-$12.70 from $11.64-$12.42 » 16:19
01/29/20
01/29
16:19
01/29/20
16:19
CACI

CACI

$266.95 /

-1.92 (-0.71%)

Consensus $12.27. Raises…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
PayPal CEO says 'delivered strong results in 2019' » 16:19
01/29/20
01/29
16:19
01/29/20
16:19
PYPL

PayPal

$116.66 /

+0.15 (+0.13%)

"PayPal delivered…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
Axos Financial reports Q2 adjusted EPS 69c, consensus 68c » 16:19
01/29/20
01/29
16:19
01/29/20
16:19
AX

Axos Financial

$27.11 /

-0.975 (-3.47%)

"We achieved net…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Mellanox reports Q4 gross margin 69.1% vs. 69.0% last year  16:19
01/29/20
01/29
16:19
01/29/20
16:19
MLNX

Mellanox

$119.24 /

+0.64 (+0.54%)

 
ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
Dolby reports Q1 EPS 47c, consensus 49c » 16:18
01/29/20
01/29
16:18
01/29/20
16:18
DLB

Dolby

$68.85 /

-0.56 (-0.81%)

Reports Q1 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Morgan Stanley homebuilding analysts to hold analyst/industry conference call » 16:18
01/29/20
01/29
16:18
01/29/20
16:18

Homebuilding &…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Earnings
Mellanox reports Q4 EPS $2.31, consensus $1.70 » 16:18
01/29/20
01/29
16:18
01/29/20
16:18
MLNX

Mellanox

$119.24 /

+0.64 (+0.54%)

Reports Q4 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
PayPal sees Q1 adjusted EPS 76c-78c, consensus 82c » 16:18
01/29/20
01/29
16:18
01/29/20
16:18
PYPL

PayPal

$116.66 /

+0.15 (+0.13%)

Sees Q1 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
CACI reports Q2 EPS $3.11, consensus $2.79 » 16:18
01/29/20
01/29
16:18
01/29/20
16:18
CACI

CACI

$266.95 /

-1.92 (-0.71%)

Reports Q revenue $1.4B,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Tonix Pharmaceuticals presents TNX-801 results at ASM Biothreats Conference » 16:18
01/29/20
01/29
16:18
01/29/20
16:18
TNXP

Tonix Pharmaceuticals

$1.39 /

-0.11 (-7.33%)

Tonix Pharmaceuticals…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
Landstar System says earnings shortfall due to insurance, claims costs » 16:17
01/29/20
01/29
16:17
01/29/20
16:17
LSTR

Landstar System

$111.33 /

-0.77 (-0.69%)

Landstar said the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
TriState Capital reports Q4 EPS 44c, consensus 44c » 16:17
01/29/20
01/29
16:17
01/29/20
16:17
TSC

TriState Capital

$24.01 /

-0.43 (-1.76%)

Reports Q4 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
Essex Property Trust sees FY20 core FFO $13.74-$14.14, consensus $14.01  16:17
01/29/20
01/29
16:17
01/29/20
16:17
ESS

Essex Property Trust

$304.00 /

-4.385 (-1.42%)

 
ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
Essex Property Trust reports Q4 core FFO $3.45, consensus $3.42 » 16:17
01/29/20
01/29
16:17
01/29/20
16:17
ESS

Essex Property Trust

$304.00 /

-4.385 (-1.42%)

"We are pleased to…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
PayPal sees FY20 adjusted EPS $3.39-$3.46, consensus $3.49 » 16:17
01/29/20
01/29
16:17
01/29/20
16:17
PYPL

PayPal

$116.66 /

+0.15 (+0.13%)

Sees FY20 revenue $20.8B…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
Landstar System reports Q4 EPS $1.27, consensus $1.42 » 16:17
01/29/20
01/29
16:17
01/29/20
16:17
LSTR

Landstar System

$111.33 /

-0.77 (-0.69%)

Reports Q4 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Earthstone Energy sees Q4 average daily sales volume up 66% at 17.4MBOE/D » 16:17
01/29/20
01/29
16:17
01/29/20
16:17
ESTE

Earthstone Energy

$4.62 /

-0.09 (-1.91%)

Guides 2020 production of…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Technical Analysis
NASDAQ market internals summary » 16:17
01/29/20
01/29
16:17
01/29/20
16:17
$NSD

NASDAQ Market Internals

$0.00 /

+ (+0.00%)

Volume was above average…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Earnings
Allegiant Travel still sees FY20 EPS $16.50-$19.00, consensus $16.98 » 16:16
01/29/20
01/29
16:16
01/29/20
16:16
ALGT

Allegiant Travel

$163.12 /

-7.57 (-4.43%)

Still sees FY20 system…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Technical Analysis
NYSE market internals summary » 16:16
01/29/20
01/29
16:16
01/29/20
16:16
$NYE

NYSE Market Internals

$0.00 /

+ (+0.00%)

Volume was average for…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Hot Stocks
Lam Research up 4.6% after reporting Q2 earnings, giving Q3 guidance  16:15
01/29/20
01/29
16:15
01/29/20
16:15
LRCX

Lam Research

$298.18 /

-3.45 (-1.14%)

 
ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
Ameriprise Financial reports Q4 adjusted EPS $4.20, consensus $4.27 » 16:15
01/29/20
01/29
16:15
01/29/20
16:15
AMP

Ameriprise

$166.41 /

+1.29 (+0.78%)

Reports Q4 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
PayPal reports Q4 adjusted EPS 86c, consensus 83c » 16:15
01/29/20
01/29
16:15
01/29/20
16:15
PYPL

PayPal

$116.66 /

+0.15 (+0.13%)

Reports Q4 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
Lam Research sees Q3 gross margin as percentage of revenue 46.5%, +/- 1%  16:15
01/29/20
01/29
16:15
01/29/20
16:15
LRCX

Lam Research

$298.18 /

-3.45 (-1.14%)

 
ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
Cimpress reports Q2 EPS $6.81, consensus $2.24 » 16:14
01/29/20
01/29
16:14
01/29/20
16:14
CMPR

Cimpress

$111.40 /

+2.5 (+2.30%)

Reports Q2 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.